MCAM is associated with metastasis and poor prognosis in osteosarcoma by modulating tumor cell migration

Abstract

Background Although there are standard treatment options for osteosarcoma (OS), the prognoses of patients with OS remain varied. Therefore, it is important to profile OS patients at a high risk of mortality to develop focused interventions. Although tumor biomarkers are closely associated with clinical outcomes, data on prognostic biomarkers for OS remain scarce. Methods We collected RNA expression profiles and clinical data of 90 OS patients from the GEO database (dataset GSE21257 and GSE39055) and 96 patients in the TARGET program. The data were analyzed using univariate Kaplan‐Meier survival analysis to screen candidate gene sets that might be associated with OS survival. Results Our analysis demonstrated that melanoma cell adhesion molecule (MCAM) was associated with overall survival of patients with OS in the three cohorts. The data showed that MCAM was upregulated in OS patients who had metastases within 5 years compared to those without metastases. GO analysis revealed that genes correlated with MCAM were mainly involved in cell migration and wound healing processes. In addition, wound healing assays and gene set enrichment analysis results from RNA sequencing data of small interfering (si)‐MCAM‐transfected OS cells demonstrated that MCAM modulated tumor cell migration. Conclusions Our data demonstrate that MCAM may be a novel prognostic biomarker for OS. MCAM is associated with increased cell migration ability and risk of metastasis, thus leading to poor prognoses in OS patients.

Hsa_circ_0097271 Knockdown Attenuates Osteosarcoma Progression via Regulating miR-640/MCAM Pathway

“…MCAM was also mentioned to be overexpressed in OS, and its high expression was related to OS metastasis and poor prognosis [27,28]. Overall, the oncogenic effect of MCAM in diverse cancers has been verified.…”

“…MCAM was strikingly elevated in small cell lung cancer with chemoresistance, and the suppression of MCAM largely repressed cancer cell proliferation and drug resistance [ 26 ]. MCAM was also mentioned to be overexpressed in OS, and its high expression was related to OS metastasis and poor prognosis [ 27 , 28 ]. Overall, the oncogenic effect of MCAM in diverse cancers has been verified.…”

Comprehensive analysis of a glycolysis and cholesterol synthesis-related genes signature for predicting prognosis and immune landscape in osteosarcoma

“…MCAM is highly expressed in various malignancies and has tight association with their growth and metastasis, such as melanoma (46), prostate cancer (47), gastric cancer (48), and lung cancer (49). Prior investigations revealed that MCAM was associated with poor prognosis of osteosarcoma patients and can improve the migration ability of osteosarcoma cells (50). For immunotherapy, MCAM deficiency significantly impairs T cell-mediated antitumor effect (51).…”

Expression of placental CD146 is dysregulated by prenatal alcohol exposure and contributes in cortical vasculature development and positioning of vessel-associated oligodendrocytes

“…Moreover, in recently patented data, it has been shown that the placenta, by releasing proangiogenic factors, could constitute a promising source of circulating biomarkers for the early diagnosis of FASD (WO2016207253, Gonzalez et al, 2016 andWO2018100143, Gonzalez et al, 2018). Several recent studies have shown that CD146 has a prognostic biomarker value for the diagnosis of cancer (Lei et al, 2015;Rapanotti et al, 2021;Du et al, 2022). This biomarker potential can be related to the angiogenic properties of CD146 (Joshkon et al, 2020), a physiological function that is dysregulated by PAE (Lecuyer et al, 2017;Léger et al, 2020a).…”